


CLAIMS

1. A compound of formula **(IA-I)**



(IA-I)

or a stereoisomer, enantiomer, diastereomer, a pharmaceutically acceptable salt, or N-oxide thereof; wherein

X is CR¹ or N;

D is monocyclic aryl or monocyclic heteroaryl; wherein D is substituted with a group E which is selected from -CONH-O-(CR^xR^y)_p-OR^x, and further D can optionally be substituted with one or more of R^z;

L₂ is -(CR^aR^b)_n-;

Cy² is substituted or unsubstituted heteroaryl;

each occurrence of R¹ and R² is hydrogen;

each occurrence of R^a and R^b may be same or different and are independently selected from hydrogen, hydroxy, halogen, and substituted or unsubstituted C₁₋₆ alkyl,


each occurrence of R^x and R^y is independently selected from hydrogen, hydroxy, substituted or unsubstituted alkyl, and substituted or unsubstituted alkoxy; wherein

each occurrence of R^z is independently hydrogen, halogen, or substituted or unsubstituted alkyl;

each occurrence of n independently represents 0, 1, 2, 3 or 4;

each occurrence of p independently represents 1, 2, 3, 4, 5, 6, 7 or 8.

2. A compound of claim 1, wherein




E is selected from $-\text{CONH}-\text{O}-(\text{CR}^x\text{R}^y)_p-\text{OR}^x$, and



X^1 , X^2 and X^3 are independently selected from $-\text{CR}^z$, $-\text{CR}^z=\text{CR}^z$, $-\text{CR}^z=\text{N}$, $-\text{N}=\text{CR}^z$, $-\text{N}=\text{N}-$, O-, -S- or -N-; wherein each occurrence of R^z is independently hydrogen, halogen, or substituted or unsubstituted alkyl.

3. A compound of any one of claims 1 and 2, wherein Cy^2 is unsubstituted heteroaryl.


4. A compound of any one of claims 1-2, wherein Cy^2 is selected from



5. A compound of claim 4, wherein Cy^2 is selected from




6. A compound of any one of claims 1-5, wherein L_2 is $-CR^aR^b-$.
7. A compound of claim 6, wherein L_2 is $-CH_2-$, $-CH(OH)-$, $-CHF-$, $-CF_2-$, $-CH(CH_3)-$ or $-C(CH_3)_2-$.
8. A compound of any one of claims 1-7, wherein L_2 is $-CH_2-$.
9. A compound of formula (IA-I):



(IA-I)

or a stereoisomer, enantiomer, diastereomer, a pharmaceutically acceptable salt, or N-oxide thereof, wherein



$-L_2-Cy^2$ is

bond to the bicyclic core in formula (IA-I);

(where the squiggly line represents the

each occurrence of R^a and R^b are independently selected from hydrogen, halogen, and substituted or unsubstituted (C_{1-6}) alkyl;

Z is selected from CR^c , S , O , NR^c , $R^cC=CR^c$, $-N=CR^c-$, and $-R^cC=N-$;

Z_1 is selected from N, NR^c and CR^c ;

Z_2 and Z_3 are independently selected from C or N;

R^c is absent or selected from hydrogen, hydroxy and halogen;

X is CR^1 or N;

D is monocyclic aryl or monocyclic heteroaryl; wherein D is substituted with a group E which is selected from $-CONH-O-(CR^xR^y)_p-OR^x$, and further D can optionally be substituted with one or more of R^z ;


each occurrence of R^1 and R^2 is hydrogen;

each occurrence of R^x and R^y is independently selected from hydrogen, hydroxy, substituted or unsubstituted alkyl, and substituted or unsubstituted alkoxy;

each occurrence of R^z is independently hydrogen, halogen, or substituted or unsubstituted alkyl, and


each occurrence of p independently represents 1, 2, 3, 4, 5, 6, 7 or 8.


10. A compound of formula (IA-I):



(IA-I)

or a stereoisomer, enantiomer, diastereomer, a pharmaceutically acceptable salt, or N-oxide thereof, wherein





L_2-Cy^2 is (where the squiggly line represents the bond to the bicyclic core in formula (IA-I);

X is CR^1 or N;

X^1 , X^2 and X^3 are independently selected from $-CR^z$, $-CR^z=CR^z$, $-CR^z=N$, $-N=CR^z$, $-N=N-$, O-, -S- or -N-;

Z is selected from CR^c , S, O, NR^c , $R^cC=CR^c$, $-N=CR^c-$, and $-R^cC=N-$;

Z_1 is selected from N, NR^c and CR^c ;

Z_2 and Z_3 are independently selected from C or N;

E is selected from $-CONH-O-(CR^xR^y)_p-OR^x$, and further D can optionally be substituted with one or more of R^z ;

each occurrence of R^1 and R^2 is hydrogen;

each occurrence of R^a and R^b may be same or different and are independently selected from hydrogen, halogen, and substituted or unsubstituted C_{1-6} alkyl;

each occurrence of R^x and R^y is independently selected from hydrogen, hydroxy, substituted or unsubstituted alkyl, and substituted or unsubstituted alkoxy;

each occurrence of R^z is independently hydrogen, halogen, or substituted or unsubstituted alkyl;


each occurrence of q independently represents 0, 1 or 2;


each occurrence of p independently represents 1, 2, 3, 4, 5, 6, 7 or 8.

11. A compound of claim 2 or claim 10, wherein X^1 and X^2 are CR^z and X^3 is independently selected from $-CR^z=CR^z$ and -S-.


12. A compound of claim 11, wherein X^1 is CH, X^2 is CR^Z and X^3 is $-CR^Z=CR^Z$, wherein R^Z is hydrogen, halogen or substituted or unsubstituted C_{1-3} alkyl.

13. A compound of any one of claims 1-12, wherein D is selected from







14. A compound of claim 13, wherein D is selected from




15. A compound of any one of claims 1-12, wherein D is selected from



16. A compound of claim 15, wherein E is selected from



17. A compound of claim 15 or claim 16, wherein E is selected from



18. A compound of claim 15, wherein each occurrence of R^z is selected from hydrogen, halogen or substituted or unsubstituted alkyl.

19. A compound of claim 18, wherein each occurrence of R^z is selected from hydrogen, fluoro, chloro, methyl or CF_3 .

20. A compound of claims 9-19, wherein each of R^a and R^b is hydrogen, alkyl or halogen.

21. A compound of any one of claims 9-20, wherein

- a) both R^a and R^b are hydrogen;
- b) R^a is methyl and R^b is hydrogen;
- c) R^a is fluoro and R^b is hydrogen;
- d) R^a and R^b both are fluoro; or
- e) R^a and R^b both are methyl.

22. A compound of any one of claims 9-21, wherein

Z is CR^c , N, S, O, $HC=CH-$ or $-N=CH-$;

Z_1 is CH or N;

Z_2 is C; and

Z_3 is C or N.

23. A compound of any one of claims 9-22, wherein

- a) Z is $-HC=CH-$, $-S-$ or $-O-$; Z_1 is CH; Z_2 is C and Z_3 is C or N;

- b) Z is -HC=CH-, Z₁ is CH ; Z₂ is C; and Z₃ is C;
- c) Z is CH, Z₁ is CH, Z₂ is C and Z₃ is N;
- d) Z is -S-, Z₁ is CH, Z₂ is C and Z₃ is C;
- e) Z is -O-, Z₁ is CH, Z₂ is C and Z₃ is C; or
- f) Z is -CH-, Z₁ is NH, Z₂ is C and Z₃ is C.

24. A compound of any one of claims 9-23, wherein each occurrence of R^c is hydrogen or fluoro.

25. A compound of any one of claims 1-24, wherein X is N or CR¹ and R¹ is H, substituted or unsubstituted C₁₋₆ alkyl, NH₂, OH, CN or CONH₂.

26. A compound of any one of claims 1-25, wherein X is N.

27. A compound of any one of claims 1-26, wherein each R² is H.

28. A compound selected from:

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl) benzamide hydrochloride:

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide 4-methylbenzenesulfonate

2-chloro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrobromide:

sodium (2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide:

2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride:

sodium (2-chloro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2-chloro-4-(3-((7-fluoro-2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride:

sodium (2,6-difluoro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide

2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride

sodium (2,6-difluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzoyl)(2-hydroxyethoxy)amide:

2-fluoro-N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl acetate:

(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl 2-(tert-butoxycarbonylamino)propanoate:

(S)-2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl 2-aminopropanoate:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl pivalate:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl isobutyrate:

2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl 2-benzamidoacetate:

2-chloro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-chloro-N-(2-hydroxyethoxy)benzamide:

4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2,6-difluoro-N-(2-hydroxyethoxy)benzamide:

sodium (4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2,6-difluorobenzoyl)(2-hydroxyethoxy)amide:

4-(3-(benzo[d]thiazol-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-fluoro-N-(2-hydroxyethoxy)benzamide:

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

2,6-difluoro-N-(2-hydroxyethoxy)-4-(3-((2-methylquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride:

N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

N-(2-hydroxyethoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-2-(trifluoromethyl)benzamide:

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-(trifluoromethyl)benzamide:

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-(trifluoromethyl)benzamide hydrochloride:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrochloride:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide hydrobromide:

N-(2-hydroxyethoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide 4-methylbenzenesulfonate:

N-(2-hydroxyethoxy)-2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

6-((5-(4-(2-hydroxyethoxycarbonyl)-3-methylphenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)methyl)quinoline 1-oxide

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-methylbenzamide:

4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)-2-methylbenzamide hydrochloride:

2-fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide:

2-fluoro-4-(3-((7-fluoroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)-N-(2-hydroxyethoxy)benzamide hydrochloride:

2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

ethyl 2-(2-chloro-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)acetate:

2-chloro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

(S)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

(R)-2-chloro-N-(2-hydroxypropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2,6-difluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

2-fluoro-N-(2-hydroxy-2-methylpropoxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide:

(S)-N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

N-(2-hydroxy-2-methylpropoxy)-2-methyl-4-(3-((2-oxo-1,2-dihydroquinolin-6-yl)methyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

(R)-N-(2-hydroxypropoxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

N-(1-hydroxy-2-methylpropan-2-yloxy)-2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

2-chloro-N-(1-hydroxy-2-methylpropan-2-yloxy)-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamide

N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-[3-(1-oxy-quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl]-benzamide

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl acetate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl isobutyrate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl pivalate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl benzoate

2-(2-methyl-4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-5-yl)benzamidoxy)ethyl furan-2-carboxylate:

and pharmaceutically acceptable salts thereof.

29. A compound selected from:

N-(2-Hydroxy-ethoxy)-2-methyl-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide

N-(2-Hydroxy-2-methyl-propoxy)-2-methyl-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide

2-Chloro-N-(2-hydroxy-ethoxy)-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide

2-Chloro-N-(2-hydroxy-2-methyl-propoxy)-4-(3-quinolin-6-ylmethyl-3H-imidazo[4,5-b]pyridin-5-yl)-benzamide:

or a pharmaceutically acceptable salt thereof.

30. A pharmaceutical composition comprising a compound of any one of claims 1-29 and a pharmaceutically acceptable carrier.

31. A compound of any one of claims 1-29 for use in inhibiting the proliferative activity of a cell.

32. A compound of any one of claims 1-29 for use in inhibiting tumor growth.

33. A compound of any one of claims 1-29 for use in inhibiting tumor metastasis.

34. A compound of any one of claims 1-29 for use in the treatment of an inflammation disorder.

35. A compound of any one of claims 1-29 for use in the treatment of cancer.

36. The compound of claim 35, wherein said cancer is a carcinoma, musculoskeletal sarcoma, soft tissue sarcoma, or hematopoietic malignancy.

37. The compound of claim 35, wherein said cancer is carcinoma of the bladder, carcinoma of the breast, carcinoma of the colon, carcinoma of the kidney, carcinoma of the liver, carcinoma of the lung, small cell lung cancer, esophageal cancer, gall bladder cancer, ovarian cancer, pancreatic cancer, stomach cancer, cervical cancer, thyroid cancer, prostate cancer, skin cancer, squamous cell carcinoma; cholangiocarcinoma cancer, tumors of mesenchymal origin, fibrosarcoma, rhabdomyosarcoma; tumors of the central and peripheral nervous system, astrocytoma, neuroblastoma, glioma, schwannoma; melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma, synovial sarcoma, rhabdomyosarcoma, MFH/fibrosarcoma, leiomyosarcoma, multiple myeloma, lymphoma, glioblastoma, astrocytoma, melanoma, mesothelioma, Wilm's tumor, hematopoietic tumors of lymphoid lineage, leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, acute myelogenous leukemias, chronic myelogenous leukemias, myelodysplastic syndrome, or promyelocytic leukemia.

38. The use of a compound of any one of claims 1-29 in the manufacture of a medicament for inhibiting the proliferative activity of a cell.

39. The use of a compound of any one of claims 1-29 in the manufacture of a medicament for inhibiting tumor growth.

40. The use of a compound of any one of claims 1-29 in the manufacture of a medicament for inhibiting tumor metastasis.

41. The use of a compound of any one of claims 1-29 in the manufacture of a medicament for the treatment of an inflammation disorder.

42. The use of a compound of any one of claims 1-29 in the manufacture of a medicament for the treatment of cancer.

43. The compound of claim 42, wherein said cancer is a carcinoma, musculoskeletal sarcoma, soft tissue sarcoma, or hematopoietic malignancy.

44. The compound of claim 42, wherein said cancer is carcinoma of the bladder, carcinoma of the breast, carcinoma of the colon, carcinoma of the kidney, carcinoma of the liver, carcinoma of the lung, small cell lung cancer, esophageal cancer, gall bladder cancer, ovarian cancer, pancreatic cancer, stomach cancer, cervical cancer, thyroid cancer, prostate cancer, skin cancer, squamous cell carcinoma; cholangiocarcinoma cancer, tumors of mesenchymal origin, fibrosarcoma, rhabdomyosarcoma; tumors of the central and peripheral nervous system, astrocytoma, neuroblastoma, glioma, schwannoma; melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma, synovial sarcoma, rhabdomyosarcoma, MFH/fibrosarcoma, leiomyosarcoma, multiple myeloma, lymphoma, glioblastoma, astrocytoma, melanoma, mesothelioma, Wilm's tumor, hematopoietic tumors of lymphoid lineage, leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, acute myelogenous leukemias, chronic myelogenous leukemias, myelodysplastic syndrome, or promyelocytic leukemia.